BioXcel Therapeutics, Inc. (BTAI)

NASDAQ: BTAI · IEX Real-Time Price · USD
28.74
+0.22 (0.77%)
Feb 1, 2023, 10:39 AM EST - Market open
0.77%
Market Cap 805.53M
Revenue (ttm) 137,000
Net Income (ttm) -137.07M
Shares Out 28.02M
EPS (ttm) -4.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 121,768
Open 28.29
Previous Close 28.52
Day's Range 27.57 - 28.88
52-Week Range 8.80 - 32.96
Beta 1.15
Analysts Buy
Price Target 48.59 (+69.07%)
Earnings Date Mar 9, 2023

About BTAI

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acu... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 8, 2018
Employees 89
Stock Exchange NASDAQ
Ticker Symbol BTAI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $48.59, which is an increase of 69.07% from the latest price.

Price Target
$48.59
(69.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC

3 weeks ago - GlobeNewsWire

BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

NEW HAVEN, Conn., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...

1 month ago - GlobeNewsWire

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer's Disease

Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer's patients in nursing homes with moderate to severe dementia

1 month ago - GlobeNewsWire

BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference

NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...

2 months ago - GlobeNewsWire

BioXcel Therapeutics to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...

2 months ago - GlobeNewsWire

BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

IGALMI™ (dexmedetomidine) well-positioned for growth in 2023 based on increasing market access, efficient targeting, favorable market drivers, and sales force expansion in all major U.S. geographies

2 months ago - GlobeNewsWire

BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022

NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...

3 months ago - GlobeNewsWire

BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022

NEW HAVEN, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...

4 months ago - GlobeNewsWire

BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

NEW HAVEN, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medic...

5 months ago - GlobeNewsWire

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

Commercially launched IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation in bipolar I or II disorder and schizophrenia in adult patients

6 months ago - GlobeNewsWire

BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference

NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran...

6 months ago - GlobeNewsWire

BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal

Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment

6 months ago - GlobeNewsWire

BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

NEW HAVEN, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran...

6 months ago - GlobeNewsWire

BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran...

7 months ago - GlobeNewsWire

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

NEW HAVEN, Conn., June 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran...

8 months ago - GlobeNewsWire

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop trans...

9 months ago - GlobeNewsWire

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults

9 months ago - GlobeNewsWire

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop trans...

9 months ago - GlobeNewsWire

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022

NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to identi...

10 months ago - GlobeNewsWire

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology

OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need

10 months ago - GlobeNewsWire

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority

Investment will support upcoming U.S. commercial launch activities of IGALMI™ and further clinical pipeline development

10 months ago - GlobeNewsWire

4 Top Stock Trades for Thursday: MSFT, TWTR, BTAI, PXD

Microsoft, Twitter, BioXcel Therapeutics and Pioneer Natural Resources were our top stock trades for Thursday. Here's the trade now.

Other symbols: MSFTPXD
10 months ago - InvestorPlace

Why BioXcel Therapeutics Stock Is Surging Today

BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI (dexmedetomidine) sublingual film for...

10 months ago - Benzinga